OnCore Login

Return to Trial Database

HCRN-LUN87-1

A Phase II Trial of VP-16, Ifosfamide and Cisplatin (VIP) Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer

Status

Study Completed

Cancer Type(s)

Lung

Study Contact

Publications

VP l6, Ifosfamide and Cisplatin (VIP) in Extensive Small Cell Lung Cancer
  • JC Miller, PJ Loehrer, J Songer, K Pennington, R Ansari, S Turner, LH Einhorn
A Phase II Hoosier Oncology Group Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) Plus Concurrent Radiation Therapy (XRT) for Previously Untreated Limited Small Cell Lung Cancer (SCLC)
  • AB Sandler, R Ansari, W Fisher, R Gonin, R Levy, LH Einhorn
A Phase II Study of Daily Oral VP-16 Plus Ifosfamide Plus Cisplatin (poVIP) for Previously Treated Recurrent Small Cell Lung Cancer (SCLC)
  • AB Sandler, PJ Loehrer, R Ansari, KW Logie, J Mortimer, R Sridhar, LH Einhorn
A Phase II Study of Daily Oral VP-16 + Ifosfamide + Cisplatin for Previously Treated Small Cell Lung Cancer (SCLC)
  • E Faylona, P Loehrer, L Einhorn, R Ansari, J McClean, S Williams
Daily Oral Etoposide Plus Ifosfamide Plus Cisplatin for Previously Treated Recurrent Small-Cell Lung Cancer
  • EA Faylona, PJ Loehrer, R Ansari, AB Sandler, R Gonin, LH Einhorn
Etoposide Plus Ifosfamide Plus Cisplatin (VIP) in Extensive Small-cell Lung Cancer
  • PJ Loehrer, SM Rynard, R Ansari, J Songer, K Pennington, LH Einhorn
Etoposide, Ifosfamide and Cisplatin (VIP) plus Concurrent Radiation Therapy for Previously Untreated Limited Small Cell Lung Cancer (SCLC): A Phase II study
  • N Hanna, R Ansari, W Fisher, J Shen, S Jung, A Sandler

Trial Locations

All sites in which the trial HCRN-LUN87-1 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278